argenx NV ADR (ARGX)vsZura Bio Limited Class A Ordinary Shares (ZURA)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
ZURA
Zura Bio Limited Class A Ordinary Shares
$5.62
+4.46%
HEALTHCARE · Cap: $510.46M
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 30.5% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
ZURA
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Intrinsic value data unavailable for ZURA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : ZURA
ZURA has a balanced fundamental profile.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : ZURA
The primary concerns for ZURA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while ZURA is a value play — different risk/reward profiles.
ZURA carries more volatility with a beta of 0.18 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 24/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Zura Bio Limited Class A Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Zura Bio Limited (Ticker: ZURA) is an innovative biotechnology company specializing in the development of groundbreaking therapies for autoimmune disorders and rare diseases. With a strong pipeline of drug candidates and a commitment to rigorous clinical trials, Zura Bio leverages advanced research methodologies to bring solutions to patients with unmet medical needs. The company is led by an experienced management team and has established strategic partnerships, positioning it favorably within the biopharmaceutical sector and enhancing its potential to drive value for investors in an evolving market landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?